Table Info

Table 1.

An overview of main studies assessing liquid biopsy in OC

Reference	Year	N° pts	Application	Method	Target	Sensitivity	Specificity
Kamat et al. [30]	2006	19	Diagnosis	Real-time PCR	Levels of cfDNA	87–91.5%	85–87%
Capizzi et al. [33]	2008	22	Diagnosis	Real-time PCR	Levels of cfDNA	77%	96%
Shao et al. [32]	2015	36	Diagnosis	bDNA technique	Levels of cfDNA	88.9%	89.5%
Widschwendter et al. [46]	2017	43	Diagnosis	Bisulfite sequencing	Methylation in 3 markers	90.7%	41.4%
Vanderstichele et al. [47]	2017	57	Diagnosis	WGS	CNA	74%	91%
Cohen et al. [50]	2018	32	Diagnosis	CancerSEEK	Genes panel & proteins	70%	99%
Pereira et al. [57]	2015	22	Prognosis	ddPCR	Levels of cfDNA	91%	60%
Akbari et al. [61]	2019	48	Prognosis	NGS	Levels of ctDNA	NR	NR
Paracchini et al. [59]	2020	46	Prognosis	sWGS	CNA	NR	NR
Minato et al. [58]	2021	11	Prognosis	ddPCR	Levels of ctDNA	NR	NR
Parkinson et al. [41]	2016	40	Therapy response	Digital PCR	TP53 mutation	71%	88%
Kim et al. [39]	2019	28	Therapy response	ddPCR	TP53 mutation	NR	NR
Oikkonen et al. [65]	2019	12	Therapy response	NGS	CNV and genes panel	NR	NR
Noguchi et al. [64]	2020	10	Therapy response	CAPP-seq	CNV	NR	NR
Rusan et al. [66]	2020	32	Therapy response	ddPCR	HOXA9 methylation	NR	NR
Christie et al. [82]	2017	30	Resistance	NGS	BRCA1/2 reversion	60%	100%
Weigelt et al. [83]	2017	19	Resistance	NGS	BRCA1/2 reversion	NR	NR
Lin et al. [81]	2019	112	Resistance	NGS	BRCA1/2 reversion	NR	NR
Hu et al. [84]	2022	25	Resistance	NGS	Genes panel	NR	NR

N° pts: number of patients; bDNA: branched DNA; CAPP-seq: cancer personalized profile by deep sequencing; cfDNA: cell-free DNA; CNA: copy number alterations; CNV: copy number variations; ctDNA: circulating tumor DNA; PCR: polymerase chain reaction; ddPCR: droplet digital PCR; NGS: next-generation sequencing; sWGS: shallow whole genome sequencing; NR: not reported; HOXA9: homeobox A9; BRCA1/2: breast cancer gene 1 and 2

Declarations

Authors contributions

ET: Conceptualization, Formal analysis, Writing—original draft. IC: Conceptualization, Formal analysis. CS: Formal analysis. All authors contributed to the manuscript revision, read, and approved the submitted version.

Conflicts of interest

IC: travel grants from Tesaro, AZ, GSK, Johson, and Johson; currently serving as external expert/advisor for AZ, GSK, Novartis, and MSD; institutional grants for clinical trials (PI): MSD, Bayer, Oasmia, Incyte. ET and CS declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Cancer Stat Facts: Ovarian Cancer [Internet]. [Cited 2023 Jan 15]. Available from: https://seer.cancer.gov/statfacts/html/ovary.html

González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833–48. [DOI] [PubMed]

Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248–66. [DOI] [PubMed]

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–96. [DOI] [PubMed] [PMC]

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53. [DOI] [PubMed]

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36. [DOI] [PubMed] [PMC]

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505. [DOI] [PubMed]

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28. [DOI] [PubMed]

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30:672–705. [DOI] [PubMed]

10.

Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;40:3952–64. [DOI] [PubMed] [PMC]

11.

Kelly RJ, Turner R, Chen YW, Rigas JR, Fernandes AW, Karve S. complications and economic burden associated with obtaining tissue for diagnosis and molecular analysis in patients with non–small-cell lung cancer in the united states. J Oncol Pract. 2019;15:e717–27. [DOI] [PubMed]

12.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. [DOI] [PubMed] [PMC]

13.

De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2018;29:2268. Erratum for: Ann Oncol. 2014;25:1729–35. [DOI] [PubMed] [PMC]

14.

McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27:15–26. [DOI] [PubMed]

15.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90. [DOI] [PubMed] [PMC]

16.

Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86. [DOI] [PubMed] [PMC]

17.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. [DOI] [PubMed] [PMC]

18.

Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–37. [DOI] [PubMed]

19.

Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018;16:370–8. [DOI] [PubMed] [PMC]

20.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30:1580–90. [DOI] [PubMed]

21.

Yang F, Tang J, Zhao Z, Zhao C, Xiang Y. Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reprod Biol Endocrinol. 2021;19:178. [DOI] [PubMed] [PMC]

22.

Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, et al. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021;15:67–79. [DOI] [PubMed] [PMC]

23.

Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143:59–78. [DOI]

24.

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280–304. [DOI] [PubMed]

25.

Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131:909–27. [DOI] [PubMed]

26.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56. [DOI] [PubMed] [PMC]

27.

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182–93. [DOI] [PubMed] [PMC]

28.

Bast RC, Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21:200s–5s. [DOI] [PubMed]

29.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50. [PubMed]

30.

Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006;1075:230–4. [DOI] [PubMed]

31.

Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116:1918–25. [DOI] [PubMed] [PMC]

32.

Shao X, He Y, Ji M, Chen X, Qi J, Shi W, et al. Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett. 2015;10:3478–82. [DOI] [PubMed] [PMC]

33.

Capizzi E, Gabusi E, Grigioni AD, De Iaco P, Rosati M, Zamagni C, et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol. 2008;17:34–8. [DOI] [PubMed]

34.

Zhou Q, Li W, Leng B, Zheng W, He Z, Zuo M, et al. Circulating cell free dna as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis. PLoS One. 2016;11:e0155495. [DOI] [PubMed] [PMC]

35.

Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. [DOI] [PubMed] [PMC]

36.

Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 2004;14:459–64. [PubMed]

37.

Park YR, Kim YM, Lee SW, Lee HY, Lee GE, Lee JE, et al. Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer. Obstet Gynecol Sci. 2018;61:328–36. [DOI] [PubMed] [PMC]

38.

Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193:662–7. [DOI] [PubMed]

39.

Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J Gynecol Oncol. 2019;30:e32. [DOI] [PubMed] [PMC]

40.

Calapre L, Giardina T, Beasley AB, Reid AL, Stewart C, Amanuel B, et al. Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Sci Rep. 2023;13:278. [DOI] [PubMed] [PMC]

41.

Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13:e1002198. [DOI] [PubMed] [PMC]

42.

Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 2003;34:337–43. [DOI] [PubMed]

43.

Wang B, Yu L, Luo X, Huang L, Li QS, Shao XS, et al. Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncol Lett. 2017;14:217–23. [DOI] [PubMed] [PMC]

44.

Zhang Q, Hu G, Yang Q, Dong R, Xie X, Ma D, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130:132–9. [DOI] [PubMed]

45.

Dong R, Yu J, Pu H, Zhang Z, Xu X. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J Int Med Res. 2012;40:681–6. [DOI] [PubMed]

46.

Widschwendter M, Zikan M, Wahl B, Lempiainen H, Paprotka T, Evans I, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 2017;9:116. [DOI] [PubMed] [PMC]

47.

Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, et al. Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clin Cancer Res. 2017;23:2223–31. [DOI] [PubMed]

48.

Maritschnegg E, Wang Y, Pecha N, Horvat R, Van Nieuwenhuysen E, Vergote I, et al. Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas: a proof-of-concept study. J Clin Oncol. 2015;33:4293–300. [DOI] [PubMed] [PMC]

49.

Maritschnegg E, Heitz F, Pecha N, Bouda J, Trillsch F, Grimm C, et al. Uterine and tubal lavage for earlier cancer detection using an innovative catheter: a feasibility and safety study. Int J Gynecol Cancer. 2018;28:1692–8. [DOI] [PubMed] [PMC]

50.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30. [DOI] [PubMed] [PMC]

51.

Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535–8. [DOI] [PubMed] [PMC]

52.

Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–5. [DOI] [PubMed]

53.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J Gynecol Cancer. 2016;26:43–51. [DOI] [PubMed] [PMC]

54.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. [DOI] [PubMed]

55.

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92. [DOI] [PubMed] [PMC]

56.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor dna profiling. Cancer Discov. 2017;7:1394–403. [DOI] [PubMed] [PMC]

57.

Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One. 2015;10:e0145754. [DOI] [PubMed] [PMC]

58.

Minato T, Ito S, Li B, Fujimori H, Mochizuki M, Yamaguchi K, et al. Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125. Gynecol Oncol Rep. 2021;38:100847. [DOI] [PubMed] [PMC]

59.

Paracchini L, Beltrame L, Grassi T, Inglesi A, Fruscio R, Landoni F, et al. Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer. Clin Cancer Res. 2021;27:2549–59. [DOI] [PubMed]

60.

Hou JY, Chapman JS, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, et al. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol. 2022;167:334–41. [DOI] [PubMed]

61.

Akbari MR, Zhu JW, Wong F, Szymiczek A, Ene G, Zhang S, et al. Evaluating the utility of ctDNA in detecting residual cancer and predicting recurrence in patients with serous ovarian cancer. J Clin Oncol. 2022;40:e17588. [DOI]

62.

Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63. [DOI] [PubMed]

63.

Krasovitsky M, Lee YC, Sim HW, Chawla T, Moore H, Moses D, et al. Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. Int J Gynecol Cancer. 2022;32:656–61. [DOI] [PubMed]

64.

Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, et al. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP‑Seq in neoadjuvant chemotherapy‑treated advanced ovarian cancer. Oncol Lett. 2020;19:2713–20. [DOI] [PubMed] [PMC]

65.

Oikkonen J, Zhang K, Salminen L, Schulman I, Lavikka K, Andersson N, et al. Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer. JCO Precis Oncol. 2019;3:1–12. [DOI] [PubMed] [PMC]

66.

Rusan M, Andersen RF, Jakobsen A, Steffensen KD. Circulating HOXA9-methylated tumour DNA: a novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Eur J Cancer. 2020;125:121–9. [DOI] [PubMed]

67.

Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72:4875–82. [DOI] [PubMed] [PMC]

68.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole–genome characterization of chemoresistant ovarian cancer. Nature. 2015;521:489–94. [DOI] [PubMed]

69.

Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samples. Oncotarget. 2015;6:30850–8. [DOI] [PubMed] [PMC]

70.

Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123:9–16. [DOI] [PubMed] [PMC]

71.

Werner B, Yuwono N, Duggan J, Liu D, David C, Srirangan S, et al. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecol Oncol. 2021;162:720–7. [DOI] [PubMed]

72.

Han MR, Lee SH, Park JY, Hong H, Ho JY, Hur SY, et al. Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer. Cancer Res Treat. 2020;52:779–88. [DOI] [PubMed] [PMC]

73.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764–75. [DOI] [PubMed] [PMC]

74.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92. [DOI] [PubMed]

75.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64. [DOI] [PubMed]

76.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, et al. Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition. J Clin Oncol. 2017;35:1240–9. [DOI] [PubMed]

77.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, et al. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization. Clin Cancer Res. 2017;23:4086–94. [DOI] [PubMed]

78.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21. [DOI] [PubMed]

79.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–20. [DOI] [PubMed] [PMC]

80.

Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29:3008–15. [DOI] [PubMed] [PMC]

81.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9:210–9. [DOI] [PubMed]

82.

Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35:1274–80. [DOI] [PubMed]

83.

Weigelt B, Comino-Mendez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017;23:6708–20. [DOI] [PubMed] [PMC]

Hu D, Guo E, Yang B, Qin X, Fu Y, Fan J, et al. Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma. Cancer Sci. 2022;113:2849–61. [DOI] [PubMed] [PMC]

85.

Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33:750–68. [DOI] [PubMed]

86.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65. [PubMed]

87.

Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis Oncol. 2022;6:e2100535. [DOI] [PubMed]

88.

Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928–37. [DOI] [PubMed] [PMC]

89.

Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 2021;7:107–10. [DOI] [PubMed] [PMC]